<?xml version="1.0" encoding="utf-8"?>
<html madcap:lastblockdepth="4" madcap:lastheight="878" madcap:lastwidth="701" xmlns:madcap="http://www.madcapsoftware.com/Schemas/MadCap.xsd">
 <head>
 </head>
 <body>
  <h1>
   Cardium Therapeutics, Inc.
  </h1>
  <div style="display: none;">
   <table cellspacing="1" class="TableStyle-dnb_tablestyle_1" style="mc-table-style: url('../Resources/TableStyles/dnb_tablestyle_1.css');">
    <col class="TableStyle-dnb_tablestyle_1-Column-Column1">
    </col>
    <col class="TableStyle-dnb_tablestyle_1-Column-Column1">
    </col>
    <col class="TableStyle-dnb_tablestyle_1-Column-Column1">
    </col>
    <thead>
     <tr class="TableStyle-dnb_tablestyle_1-Head-Header1">
      <th class="TableStyle-dnb_tablestyle_1-HeadE-Column1-Header1">
       DUNS
      </th>
      <th class="TableStyle-dnb_tablestyle_1-HeadE-Column1-Header1">
       Hoovers ID
      </th>
      <th class="TableStyle-dnb_tablestyle_1-HeadD-Column1-Header1">
       Tier
      </th>
     </tr>
    </thead>
    <tbody>
     <tr class="TableStyle-dnb_tablestyle_1-Body-Body1">
      <td class="TableStyle-dnb_tablestyle_1-BodyB-Column1-Body1" style="text-align: center;">
        183916480
      </td>
      <td class="TableStyle-dnb_tablestyle_1-BodyB-Column1-Body1" style="text-align: center;">
       146280
      </td>
      <td class="TableStyle-dnb_tablestyle_1-BodyA-Column1-Body1" style="text-align: center;">
       3
      </td>
     </tr>
    </tbody>
   </table></div><MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/H2 Synopsis.flsnp" /><p>
   At the heart of Cardium Therapeutics is a hope to hit it big with one of its assorted holdings. Its Cardium Biologics unit includes lead candidate Generx which is in development as a treatment for candidates ischemic heart disease (such as angina), and restoring heart functioning after a heart attack. Meanwhile its Tissue Repair Company business received
   <company id="144161">
    FDA
   </company>
   approval for Excellagen, a topical gel intended to promote healing diabetic foot ulcers and other wounds, in 2012. A third business, To Go Brands, develops and sells nutritional supplements and skin care products.
  </p><MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/XML text end.flsnp" /><MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/H2 Strategy.flsnp" />
  <p>
   Cardium is focused on advancing its lead candidate (Generx) through the clinical development process. The company is also evaluating Generx as a lower-cost therapy for cardiology patients in developing and newly industrialized countries.
  </p>
  <p>
   Rather than commercialize Excellagen on its own, the company is partnering with other companies with experience in taking new products to market.
  </p>
  <MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/XML text end.flsnp" /><MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/H2 Company Background.flsnp" />
  <p>
   Cardium Therapeutics sold its Innercool Therapies subsidiary -- which made the Celsius Control, CoolBlue, and Rapid Blue systems that help warm or cool patients with catheters or wraps -- to
   <company id="41823">
    Royal Philips Electronics
   </company>
   for $11 million in 2009. Cardium acquired Innercool Therapies in 2006  and built up its sales force to commercialize the Celsius Control System.
  </p>
 <MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/XML text end.flsnp" /></body>
</html>
